Guangzhou LintonPharm Co.,Ltd.

Science & Conscience for Life Affordable Biomedical Cure

General Information
Company Name
Guangzhou LintonPharm Co.,Ltd.
Founded Year
2017
Location (Offices)
China +1
Founders / Decision Makers
Number of Employees
5
Industries
Biotechnology, Life Sciences
Funding Stage
-
Social Media

Guangzhou LintonPharm Co.,Ltd. - Company Profile

LintonPharm is a biotechnology startup founded in 2017. Specializing in the biotechnology industry, the company has garnered attention from investors. However, specific details about its headquarter location, last investment, and investors are currently unavailable. As a venture capital firm, it's crucial to closely monitor LintonPharm's progress and potential for growth in the biotechnology sector. With an increasingly competitive landscape, keeping an eye on emerging companies like LintonPharm is essential for identifying investment opportunities and staying informed about the latest developments within the biotechnology industry.

Funding Rounds & Investors of Guangzhou LintonPharm Co.,Ltd. (0)

View All

There is no investment information

Latest News of Guangzhou LintonPharm Co.,Ltd.

View All

No recent news or press coverage available for Guangzhou LintonPharm Co.,Ltd..

Similar Companies to Guangzhou LintonPharm Co.,Ltd.

View All
Y-Biologics - Similar company to Guangzhou LintonPharm Co.,Ltd.
Y-Biologics Exploring antibodies, creating novel therapeutics
Context Therapeutics - Similar company to Guangzhou LintonPharm Co.,Ltd.
Context Therapeutics Advancing T Cell Engagers for Solid Tumors
BioNTech SE - Similar company to Guangzhou LintonPharm Co.,Ltd.
BioNTech SE Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases.
Dima Biotechnology - Similar company to Guangzhou LintonPharm Co.,Ltd.
Dima Biotechnology Recombinant monoclonal antibodies and membrane proteins for drug discovery.
Akeso Biopharma - Similar company to Guangzhou LintonPharm Co.,Ltd.
Akeso Biopharma First in class and best in class therapeutic antibodies for patients worldwide. #9926.HK